Search results for "CLO"

showing 10 items of 9986 documents

Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange

2012

Systemic lupus erythematosus (SLE) has been described as a cause of thrombotic microangiopathy, especially thrombotic thrombocytopenic purpura (TTP). Haemolytic-uraemic syndrome (HUS) is less frequent in SLE. We report a case of such an association during an episode of severe lupus nephritis in a young woman, who was successfully treated with steroids, cyclophosphamide and especially plasma exchange with plasma replacement. This report highlights the importance of recognising atypical HUS in SLE patients by looking for schistocytes in case of haemolytic anemia with a negative antiglobulin test, in order to begin plasma exchange.

medicine.medical_specialtyThrombotic microangiopathyCyclophosphamidebusiness.industryAnemiaThrombotic thrombocytopenic purpuraLupus nephritismedicine.diseaseGastroenterologySchistocytePharmacotherapyimmune system diseaseshemic and lymphatic diseasesInternal medicineInternal MedicineMedicineskin and connective tissue diseasesbusinessAnti-SSA/Ro autoantibodiesmedicine.drugInternal Medicine Journal
researchProduct

Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation.

1998

Background —This study was performed to analyze the influence of either aspirin, ticlopidine, or their combination on platelet activation and aggregation parameters after stent implantation. Methods and Results —Sixty-one patients with successful implantation of a single Palmaz-Schatz stent in a native coronary artery were randomly assigned to either group A (aspirin 300 mg/d+ticlopidine 2×250 mg/d), group B (ticlopidine 2×250 mg/d), or group C (aspirin 300 mg/d). Platelet activation was evaluated on days 1, 7, and 14 by flow cytometry measurement of expression of CD62p (p-selectin) and the binding of fibrinogen to the platelet surface glycoprotein IIb/IIIa receptor. Platelet aggregation w…

medicine.medical_specialtyTiclopidineTime FactorsPlatelet Aggregationmedicine.medical_treatmentUrologyCoronary DiseasePlatelet Glycoprotein GPIIb-IIIa ComplexFibrinogenPhysiology (medical)MedicineHumansPlateletPlatelet activationTiclopidineAngioplasty Balloon CoronaryAspirinChemotherapyAspirinbusiness.industryStentFibrinogenP-SelectinAnesthesiaPlatelet aggregation inhibitorDrug Therapy CombinationStentsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugCirculation
researchProduct

The nicotinic acetylcholine receptor agonist (±)-epibatidine increases FGF-2 mRNA and protein levels in the rat brain

2000

Abstract In a previous work, we showed that acute intermittent nicotine treatment up-regulates the level of fibroblast growth factor-2 (FGF-2) mRNA in brain regions of tel- and mesencephalon of rats suggesting that neuroprotective effect of (−)nicotine may, at least in part, involve an activation of the neuronal FGF-2 signalling. The present experiments were designed to extend the study on the nicotinic receptor mediated up-regulation of FGF-2 mRNA levels to the use of the potent nicotinic acetylcholine receptor (nAChR) agonist (±)-epibatidine. The (±)-epibatidine treatment led to a strong and long lasting up-regulation of FGF-2 mRNA expression in the cerebral cortex, in the hippocampal for…

medicine.medical_specialtyTime FactorsNicotinic acetylcoline receptor agonistPyridinesBlotting WesternNerve Tissue ProteinsNicotinic AntagonistsFibroblast growth factor-2MecamylamineBiologyHippocampusRats Sprague-DawleyNicotineCellular and Molecular NeuroscienceInternal medicineMecamylaminemedicineGlial cell line-derived neurotrophic factorAnimalsGlial Cell Line-Derived Neurotrophic FactorNerve Growth FactorsNicotinic AgonistsRNA MessengerMolecular BiologyIn Situ HybridizationEpibatidineCerebral CortexBrain-derived neurotrophic factorDose-Response Relationship DrugBrain-Derived Neurotrophic FactorBrainBridged Bicyclo Compounds HeterocyclicCorpus StriatumRatsSpecific Pathogen-Free OrganismsNicotinic acetylcholine receptorEndocrinologyNicotinic agonistGene Expression RegulationEpibatidinebiology.proteinFibroblast Growth Factor 2Alpha-4 beta-2 nicotinic receptorFibroblast growth factor receptor-1medicine.drugMolecular Brain Research
researchProduct

Differential regulation of interleukin-6 expression in human fibroblasts by tumor necrosis factor-alpha and lymphotoxin.

1990

The treatment of human diploid fibroblasts with tumor necrosis factor (TNF)-alpha and with lymphotoxin (LT) is associated with induction of interleukin-6 (IL-6) transcripts with TNF-alpha being 10-fold more potent than LT. Here we report on the TNF-alpha/LT-induced signaling mechanisms responsible for the regulation of IL-6 gene expression in these cells. Run-on assays demonstrated that both TNF-alpha and LT increase IL-6 mRNA levels by transcriptional activation of this gene. Stability studies of IL-6 transcripts in fibroblasts showed that TNF-alpha delayed IL-6 mRNA decay but not LT. The induction of IL-6 transcripts by TNF-alpha and LT was not inhibited by the isoquinoline sulfonamide de…

medicine.medical_specialtyTime FactorsTranscription Geneticmedicine.medical_treatmentCellular differentiationBiophysicsCycloheximideBiologyBiochemistrychemistry.chemical_compoundStructural BiologyInternal medicineGene expressionGeneticsmedicineHumansRNA MessengerMolecular BiologyLymphotoxin-alphaProtein kinase CCells CulturedProtein Kinase CInterleukin-6Tumor Necrosis Factor-alphaCell BiologyFibroblastsMolecular biologyKineticsCytokineLymphotoxinEndocrinologychemistryGene Expression RegulationProtein BiosynthesisTumor necrosis factor alphaSignal transductionFEBS letters
researchProduct

Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner – A quantitative in vitro gene expression analy…

2010

Bisphosphonates are widely used in the clinical treatment of bone diseases with increased bone resorption. In terms of side effects, they are known to be associated with osteonecrosis of the jaw (BONJ). There are two groups of bisphosphonates: the nitrogen-containing bisphosphonates, e.g. zoledronate and ibandronate, and the non-nitrogen-containing bisphosphonates, e.g. clodronate. Their impact on bone metabolism seems to differ. The objective of this study was to compare the osteogenic differentiation potency of these two pharmacologic groups. Human osteoblasts were stimulated with zoledronate and ibandronate at concentrations of 5×10(-5) M, 5×10(-6) M and 5×10(-7) M over the experimental …

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentOsteocalcinCell Culture TechniquesCore Binding Factor Alpha 1 SubunitZoledronic AcidIbandronic acidBone remodelingInternal medicineHumansMedicineIbandronic AcidHomeodomain ProteinsMSX1 Transcription FactorOsteoblastsBone Density Conservation AgentsDiphosphonatesDose-Response Relationship DrugbiologyReverse Transcriptase Polymerase Chain Reactionbusiness.industryImidazolesCell DifferentiationOsteoblastDLX5BisphosphonateRUNX2Zoledronic acidmedicine.anatomical_structureEndocrinologyGene Expression RegulationOtorhinolaryngologyOsteocalcinbiology.proteinSurgeryBone RemodelingClodronic AcidOral SurgerybusinessBiomarkersTranscription Factorsmedicine.drugJournal of Cranio-Maxillofacial Surgery
researchProduct

Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia

2014

Oral administration of low-dose cyclophosphamide in pets with spontaneously occurring malignant neoplasms has become a common practice in veterinary medicine. The purpose of this retrospective study was to investigate toxicity events in cats with spontaneous malignancies receiving cyclophosphamide as a metronomic therapy for at least 1 month. The number and severity of clinical, haematological and biochemical adverse events were recorded according to the Veterinary Cooperative Oncology Group’s Common Terminology Criteria for Adverse Events v1.1 classification scheme. Twenty-four cats were enrolled in the study with a total number of 27 neoplasms: 13 sarcomas, 12 carcinomas, one melanoma an…

medicine.medical_specialtyToceranibCyclophosphamideCat DiseasesGastroenterologyDisease-Free SurvivalDrug Administration ScheduleMetastasisNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsSmall AnimalsAdverse effectAntineoplastic Agents AlkylatingCyclophosphamideNeoplasm StagingRetrospective StudiesCATSDose-Response Relationship Drugbusiness.industryCommon Terminology Criteria for Adverse Eventsmedicine.diseaseSurgeryThalidomideToxicityCatsbusinessmedicine.drugJournal of Feline Medicine and Surgery
researchProduct

A randomized clinical trial of topical dexamethasone vs. cyclosporine treatment for oral lichen planus

2021

BACKGROUND Oral lichen planus (OLP) is a common, frequently symptomatic, immune-mediated disease. Various treatments have been used for symptomatic OLP, including corticosteroids and immunosuppressants administered topically or systemically. The aim of this study was to compare the effectiveness of topical dexamethasone vs. topical cyclosporine in treatment of symptomatic OLP. MATERIAL AND METHODS Thirty-two patients with biopsy-proven symptomatic OLP were randomly assigned to two therapeutic groups: dexamethasone 2mg/5ml or cyclosporine 100mg/ml, both administered topically in a swish and spit method three times a day for 4 weeks. The patients were followed up for a total of 6 months. Asse…

medicine.medical_specialtyTopical dexamethasoneAdministration TopicalGastroenterologyDexamethasonelaw.inventionRandomized controlled triallawInternal medicinemedicine3-d printingHumansGeneral DentistryDexamethasoneUNESCO:CIENCIAS MÉDICASbusiness.industryorthognathic surgerysplintsmedicine.diseaseDysphagiaTreatment periodDiscontinuationClinical trialOtorhinolaryngologydata accuracyCyclosporineSurgeryOral lichen planusmedicine.symptombusinessImmunosuppressive Agentsmedicine.drugLichen Planus Oral
researchProduct

Transcatheter embolization of a large aberrant systemic artery to an intralobar pulmonary sequestration using an Amplatzer vascular plug in an adoles…

2017

International audience

medicine.medical_specialtyTranscatheter embolizationVascular plug[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine030204 cardiovascular system & hematology[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicinePulmonary sequestration03 medical and health sciences0302 clinical medicineText mining[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineRadiology Nuclear Medicine and imagingEndovascular treatment030212 general & internal medicineLetter to the EditorGeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)ComputingMilieux_MISCELLANEOUS[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingbusiness.industrymedicine.diseaseSurgerymedicine.anatomical_structureRadiologybusinessArtery
researchProduct

Catheter-based closure of a large atrial septal defect with inferior rim deficiency using pulmonary vein slide-out assisted implantation technique: a…

2021

Abstract Background Transcatheter approach for large and complex atrial septal defects may represent a therapeutic challenge, particularly when the postero-inferior rim is deficient and floppy. Case summary Here, we describe a successful catheter-based closure of a large (>30 mm) secundum atrial septal defect associated with postero-inferior rim deficiency in a 35-year-old female with congestive heart failure using pulmonary vein slide-out assisted implantation technique. Discussion Inferior–posterior rim deficiency is a well-known risk factor for device instability or embolization. Transcatheter closure may represent a safe and effective alternative to the traditional surgical appro…

medicine.medical_specialtyTransoesophageal echocardiographybusiness.industrymedicine.medical_treatmentSeptum secundummedicine.diseaseAtrial septal defectsPulmonary veinSurgeryCathetermedicine.anatomical_structureAtrial septal rims deficiencyHeart failureCase reportmedicinePatent foramen ovaleAtrial septal defectAcademicSubjects/MED00200Transcatheter closureEmbolizationAtrium (heart)Atrial septal defect Atrial septal rims deficiency Case report Transcatheter closure Transoesophageal echocardiographyCardiology and Cardiovascular Medicinebusiness
researchProduct

Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotep…

2021

ABSTRACT One hundred and sixty-one patients underwent haploidentical stem cell transplantation (haploSCT) with thiotepa, busulfan, and fludarabine conditioning followed by post-transplantation cyclophosphamide (PTCy) (on days +3 and +4) and tacrolimus as graft-versus-host disease prophylaxis. Forty-two percent of patients had a high or very high revised Disease Risk Index (rDRI), 55% had an European Society for Blood and Marrow Transplantation risk score (EBMT-RS) ≥4, and 36% had an age-adjusted Hematopoietic Cell Transplant Comorbidity Index (HCT-CI-age) score ≥3. Each of these was considered an unfavorable score. Using the pretransplantation unfavorable scores that had an independent impa…

medicine.medical_specialtyTransplantation ConditioningPredictive transplantation scoresCyclophosphamideAcute myelogenous leukemiaGraft vs Host DiseaseThioTEPAInternal medicinemedicineHumansImmunology and AllergyBusulfanCyclophosphamideTransplantationFramingham Risk Scorebusiness.industryIncidence (epidemiology)Hematopoietic Stem Cell TransplantationCell BiologyHematologyHaploidentical transplantation with TBF conditioningTacrolimusFludarabineTransplantationsurgical procedures operativeMolecular MedicinebusinessThiotepaVidarabineBusulfanmedicine.drugTransplantation and Cellular Therapy
researchProduct